Change the keyword or sentiment above, then click Apply.
Tuesday, 15 Sep 20261 update
↗ AI sentiment: Bullish
82% confidence
HDFC Bank Succession Plan Wins 'Buy' Ratings; TPs at ₹880 & ₹1050
HDFC Bank's succession planning boosts investor confidence; Jefferies and Kotak maintain 'Buy' ratings with TPs of Rs 880 & Rs 1050.
Solar Industries' Omnia acquisition aids EPS growth; UBS favors Sun Pharma, Kalyan Jewellers, and Indian Hotels citing strong growth prospects.
Source: NDTV Profit
Friday, 11 Sep 20263 updates
↔ AI sentiment: Neutral
75% confidence
Sun Pharma: Subsidiaries Resolve US Generic Drug Pricing Antitrust Case For A Secret Amount, Not Admitting Fault.
↔ AI sentiment: Neutral
78% confidence
Sun Pharma Settles US Antitrust Case; No Wrongdoing Admitted
Sun Pharma subsidiaries settle U.S. antitrust lawsuit with confidential terms.
No wrongdoing admitted; settlement avoids further litigation and covers related entities.
Source: ScoutQuest
↗ AI sentiment: Bullish
69% confidence
Sun Pharma: Bernstein on Sun Pharma Outperform, Target Price ₹2,235, as Moody’s Baa1/Stable and S&P preliminary BBB+/Stable ratings validate the thesis that combined cash flows can service the full $11.75bn Organon acquisition debt while sustaining R&D, manufacturing and shareholder returns; sees ~$1bn synergies over 3–4 years, with FY27–29 likely limited dividends/buybacks and FY28 focus on CEO-led integration, synergy extraction and supply-chain integration.
Thursday, 10 Sep 20261 update
↔ AI sentiment: Neutral
57% confidence
GLP-1 Weight-loss Boom Pushes Pharma Companies Into Nutraceuticals And Wellness, Opening New Growth Avenues - Newspaper
Wednesday, 09 Sep 20262 updates
↔ AI sentiment: Neutral
91% confidence
Sun Pharma: Co. Incorporates Unit "Sun Pharma Global Treasury Centre IFSC Limited" In Gift City, Gandhinagar; Entity To Operate As Global Treasury Centre For Sun Pharma Group.
↔ AI sentiment: Neutral
85% confidence
Sun Pharma Sets Up Global Treasury Unit in GIFT City
Sun Pharma has incorporated Sun Pharma Global Treasury Centre IFSC Ltd as a wholly-owned subsidiary on 08 Sep 2026 in GIFT City, Gujarat.
The subsidiary will serve as the Global Treasury Centre, handling treasury, funding, liquidity, and cash management for Sun Pharma Group.
Source: BSE
Tuesday, 08 Sep 20261 update
↔ AI sentiment: Neutral
68% confidence
Sun Pharma Gets Investment-Grade Ratings for $11.75B Organon Bid
Sun Pharma received 'BBB+' and 'Baa1' investment-grade ratings from S&P and Moody's for its $11.75-billion Organon acquisition bid.
The deal, expected to close by March 2027, will double Sun Pharma's revenue to $14 billion by FY28, enhancing its global reach.
Source: The Hindu Business Line
Monday, 07 Sep 20261 update
↔ AI sentiment: Neutral
67% confidence
Sun Pharma Sees ₹16.82 Cr Block Trade at ₹1,894.80/Share
Sun Pharma saw an NSE block trade of Rs. 16.82 Cr for ~88,743 shares.
Shares were traded at Rs. 1,894.80 per share.
Source: Livesquawk
Thursday, 03 Sep 20261 update
↔ AI sentiment: Neutral
94% confidence
Sun Pharmaceutical Industries: Plans Meetings With Analysts and Investors On September 10, 16, and 17
Wednesday, 02 Sep 20264 updates
↗ AI sentiment: Bullish
93% confidence
Sun Pharma: Secures 2-year Us Tariff Relief In Mfn Drug-pricing Deal
↔ AI sentiment: Neutral
73% confidence
Bernstein Sets ₹2,235 Target for Sun Pharma, Highlights Medicaid Boost
Bernstein maintains an 'Outperform' rating on Sun Pharma with a ₹2,235 target.
MFN agreement may expand its $1.2–$1.3bn franchise via Medicaid pricing improvements.
Source: Livesquawk
↗ AI sentiment: Bullish
81% confidence
Sun Pharma: HSBC on Sun Pharma Maintains Buy with Target Price of ₹2,120 as the MFN deal removes the tariff overhang for two years, with limited estimated FY29 EPS impact and further clarity awaited.
↗ AI sentiment: Bullish
93% confidence
Sun Pharma: Bernstein on Sun Pharma Maintains Outperform with Target Price of ₹2,235 as the MFN agreement protects and expands its US$1.2–1.3bn innovative-medicines franchise, potentially improving patient access and biologic adoption through lower Medicaid pricing and reduced authorization barriers.
Tuesday, 01 Sep 20264 updates
↗ AI sentiment: Bullish
85% confidence
Sun Pharma Secures 2-Year US Tariff Relief with Pricing Deal
Sun Pharma signs US drug pricing deal, securing 2-year tariff relief.
Extends MFN pricing to Medicaid, betting on market certainty in US.
Source: Moneycontrol
↗ AI sentiment: Bullish
72% confidence
Sun Pharma: Supports White House's Medicine Access Push With Most Favored Nation Pricing For US Medicaid, Deferring Section 232 Tariffs And Acquiring Organon For $11.75 Billion To Boost US Market Growth.
↗ AI sentiment: Bullish
83% confidence
Sun Pharma Gains on US Pricing Deal, Shares Up 11.5% YTD
Sun Pharma gains focus after White House pricing deal, securing a 2-year tariff reprieve on innovative drugs.
US market contributes 27% of Sun Pharma's revenue; shares rose 11.5% YTD, closing at ₹1,925.
Source: CNBC TV 18
↔ AI sentiment: Neutral
74% confidence
Sun Pharma Pledges Affordable U.S. Drugs, Highlights 27% Revenue from Market
Sun Pharma joins White House event, commits to affordable U.S. medicines via MFN pricing for Medicaid and innovative launches.
U.S., Sun Pharma's largest market, contributes 27% of revenue; recent $11.75B Organon acquisition underscores commitment.
Source: BSE
Thursday, 27 Aug 20261 update
↗ AI sentiment: Bullish
80% confidence
India Govt Seeks Joint Ventures With Japanese Companies In Pharma And Shipbuilding, Says Goyal